James Tait, BSc (Hons), Simon Erridge, MBBS, BSc (Hons), and Mikael H. Sodergren, FRCS, PhD, Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Simon Erridge, and Mikael H. Sodergren, Sapphire Medical Clinics, London, UK.
J Pain Palliat Care Pharmacother. 2023 Jun;37(2):170-177. doi: 10.1080/15360288.2023.2174633. Epub 2023 Feb 10.
The UK Medical Cannabis Registry is the largest real world data platform for medical cannabis outcomes in the UK, providing insight into clinical outcomes and monitoring safety of this novel therapy. This study aims to assess the functionality and accessibility of the online data collection platform and patient priorities for future research. Descriptive statistics were used to analyze quantitative data. For open-ended questions an inductive thematic analysis was performed. 600 responses were recorded. 554 (92.3%) patients had used the platform. 272 (90.4%) patients believed it was easy to input medications. 52 (8.67%) patients recorded an adverse event with 38 (73.1%) finding it easy to record. 535 (96.6%) patients had completed health questionnaires with 490 (91.6%) patients finding this easy to do. 553 (92.2%) patients agreed that contributing to the registry would impact the medical care of future patients. "Assessing the impact of medical cannabis on quality of life generally" was the top research priority for 357 (59.3%) patients. This study demonstrates that most enrolled patients found the platform easy to use and believed they were positively impacting future medical cannabis patient care. Future patient research priorities included assessment of quality of life and condition-specific outcomes.
英国医用大麻注册处是英国最大的医用大麻结果真实世界数据平台，为了解这种新型疗法的临床结果和监测安全性提供了深入的见解。本研究旨在评估在线数据收集平台的功能和可及性，以及患者对未来研究的重点。使用描述性统计分析定量数据。对于开放式问题，采用归纳主题分析。记录了 600 份回复。554 名（92.3%）患者使用过该平台。272 名（90.4%）患者认为输入药物很容易。52 名（8.67%）患者记录了不良反应，其中 38 名（73.1%）患者认为很容易记录。535 名（96.6%）患者完成了健康问卷，其中 490 名（91.6%）患者认为很容易完成。553 名（92.2%）患者同意向注册处提供信息将影响未来患者的医疗护理。357 名（59.3%）患者将“评估医用大麻对生活质量的总体影响”列为首要研究重点。这项研究表明，大多数登记患者发现该平台易于使用，并认为他们正在积极影响未来的医用大麻患者护理。未来患者的研究重点包括评估生活质量和特定疾病的结果。
